Therapeutic Focus
Onconova is focused on discovering and developing novel products for patients with cancer.
About Onconova Therapeutics
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and a dose-escalation and expansion Phase 1 trial is planned in the U.S. to commence in the first half of 2021. Onconova’s product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with advanced KRAS+ lung adenocarcinoma in combination with nivolumab.
Onconova Therapeutics was incorporated in 1998 in Delaware and began trading on the NASDAQ stock exchange under the ticker symbol ONTX in July, 2013.
Onconova Therapeutics News Releases
- Onconova Therapeutics, Inc. to Present at NobleCon17 Virtual Event January 14, 2021
- Onconova Therapeutics, Inc. Announces $8.7 Million Public Offering January 7, 2021
- Onconova Therapeutics Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300 December 21, 2020
- Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300 November 23, 2020
- Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update November 12, 2020
- Onconova Therapeutics to Provide Corporate Update and Third Quarter 2020 Financial Results on November 12, 2020 November 5, 2020
